Supplementary Table 4 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy

Marcus Gerlach; Saskia Schmitt; Philipp Cyprys; Marc‐André Kasper; Isabelle Mai; Magdalena Klánová; Andreas Maiser; Heinrich Leonhardt; Christian P. R. Hackenberger; Günter R. Fingerle-Rowson; Annette M. Vogl; Dominik Schumacher; Jonas Helma

doi:10.1158/1535-7163.31248868

Supplementary Table 4 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy

2026 Open access

Read full text

Authors: Marcus Gerlach, Saskia Schmitt, Philipp Cyprys, Marc‐André Kasper, Isabelle Mai, Magdalena Klánová, Andreas Maiser, Heinrich Leonhardt, Christian P. R. Hackenberger, Günter R. Fingerle-Rowson, Annette M. Vogl, Dominik Schumacher

+1 more

Jonas Helma

DOI: 10.1158/1535-7163.31248868

Cited by: 0

Abstract

Study design of TUB-010 versus Adcetris repeated dose toxicity study in rats

Fields of Study & Subjects

Monoclonal and Polyclonal Antibodies Research Lymphoma Diagnosis and Treatment Immunotoxicology and immune responses

Publication details

Publication date: 4 February 2026